Fermenta Biotech's board will meet on May 26, 2026 to approve audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026.
The board will also consider recommending a final equity dividend for FY 2025-26, subject to shareholder approval.
The company's trading window has been closed since April 1, 2026 and will remain shut until 48 hours after the May 26 results declaration.
This notice is a regulatory disclosure pursuant to SEBI LODR Regulation 29 for informing the exchange of a scheduled board meeting.